Molecular Positron Emission Tomography and PET/CT Imaging in Urological Malignancies

Powles, Tom; Murray, Iain; Brock, Cathryn; Oliver, R. T. D.; Avril, Norbert

doi:10.1016/j.eururo.2007.01.061

Cited by 138 publications

(75 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, there was no significant correlation between serum PSA levels and Gleason score with SUVmax in F-FDG PET/CT scans do not play an important role in the primary diagnosis or staging of prostate cancer. This is because detecting prostate cancer using 18 F-FDG PET/ CT scans is limited by urinary excretion of the radiotracer, as well as the low metabolic activity of prostate cancer (Powles et al, 2007). In addition, because the uptake of 18 F-FDG can result in a focal or diffuse pattern under benign conditions (prostatitis or BPH), it is difficult to distinguish malignant or benign lesions from abnormal prostatic uptake in 18 F-FDG PET/CT images (Hoh et al, 1998;Lawrentschuk et al, 2006;Kao et al, 2008).…”

Section: Resultsmentioning

confidence: 99%

Incidental Abnormal FDG Uptake in the Prostate on 18-fluoro-2-Deoxyglucose Positron Emission Tomography-Computed Tomography Scans

Kang¹,

Seo²,

Lee³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Incidental Abnormal FDG Uptake in the Prostate on 18-fluoro-2-Deoxyglucose Positron Emission Tomography-Computed Tomography Scans

Kang¹,

Seo²,

Lee³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Numerous PET measurements of 11 C-acetate kinetics have shown three distinct phases in its accumulation, which allow to delineate biochemical processes described aboverapid uptake reflects delivery and is used to measure regional blood flow, rapid washout reflects oxidation in TCA and is used to measure oxygen consumption [5] whilst plateau of retained activity is related to the accumulation of the tracer in the lipid pool and is used in oncological studies [7].…”

Section: Acetate Metabolic Routsmentioning

confidence: 99%

“…Many groups started to use this molecule to study different tumours, especially those that are difficult to detect with 18 F-FDG PET. The usefulness of 11 C-acetate and its complementary role to 18 F-FDG is well documented in hepatocellular carcinoma, astrocytoma, renal cell carcinoma, low-grade malignancies in lung cancer and prostate cancer [6,7]. Moreover, indication exist that 2-[ 14 C]acetate might be incorporated into the amino acid pool of glial tumours, thus making 11 C-acetate labelled into its methyl position a potential imaging tracer for gliomas and meningiomas [8,9].…”

mentioning

confidence: 99%

PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective

Soloviev

Fini

Chierichetti

et al. 2008

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose In the present study, the potential clinical role of 11 C-acetate PET mainly in the differential diagnosis, in the staging and in the follow-up of prostate cancer patients is reported. Methods Each of the above points has been accurately investigated by studying the specific biochemical and radiobiochemical behaviour of this positron emitter compound. Results and Conclusion The imaging quality of 11 C-acetate PET and its unique mechanisms of cellular uptake, make such radiotracer a powerful tool in evaluating all the steps of the prostatic cancer.Keywords PET imaging . 11 C-acetate . Prostate cancer . Biochemical perspective . Radiochemical perspective . Clinical perspective Radiolabelled acetate is a simple metabolic probe used in the study of healthy and malignant tissues, organs and glands. The use of labelled acetate in biochemical research started decades ago, and involved studying glial metabolism in the brain by MRI and myocardial metabolism by PET. A new potential for the use of this molecule in conjunction with 11 C has been established for use in oncological PET investigations.Clinical experience in some of our institutions in imaging prostate cancer by PET with 11 C-acetate appeals to the wider use of this tracer provided that the core questions underlying its biochemistry are solved. Preliminary studies performed at Castelfranco Veneto PET centre have allowed accurate "de novo" diagnosis of prostate cancer with a very low rate of false-positive cases (global accuracy approaching 90%), thus potentially playing an important role in early differential diagnosis between benign and malignant prostate lesions [1]. Moreover, the use of 11 C-acetate PET at Geneva University Hospital in the clinical setting of prostate cancer relapse after radical surgery allowed the detection of recurrences at a very early phase, i.e. in patients having only slightly increased PSA levels (lower than 0.8 ng/ml) [2]. This article deals on the early and current use of radiolabelled acetate with an attempt to understand the underlying biochemical and radiochemical principles that play a role in its applications. Early research with 11 C-acetateThe use of 11 C-acetate on animals and humans started in the early 1980s to study myocardial metabolism [3] and proved useful in patients with coronary heart disease. In these studies, a correlation between radioactivity washout from Eur J Nucl Med Mol Imaging (2008) 35:942-949

show abstract

“…Fluorodeoxyglucose-positron emission tomography (FDG-PET) has failed to show any benefit over CT scan for initial staging of TC. 6 Overall 7 primary tumour should be performed before any systemic treatment, unless there is a significant burden of metastatic disease necessitating immediate systemic therapy.…”

Section: Stagingmentioning

confidence: 99%

Diagnosis and management of testicular cancers

Rodríguez‐Vida

2013

Trends Urol & Men's Health

View full text Add to dashboard Cite

show abstract

Molecular Positron Emission Tomography and PET/CT Imaging in Urological Malignancies

Cited by 138 publications

References 49 publications

Incidental Abnormal FDG Uptake in the Prostate on 18-fluoro-2-Deoxyglucose Positron Emission Tomography-Computed Tomography Scans

Incidental Abnormal FDG Uptake in the Prostate on 18-fluoro-2-Deoxyglucose Positron Emission Tomography-Computed Tomography Scans

PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective

Diagnosis and management of testicular cancers

Contact Info

Product

Resources

About